Surgery Partners (NASDAQ:SGRY) Price Target Cut to $34.00 by Analysts at Macquarie

Surgery Partners (NASDAQ:SGRY) had its price objective reduced by Macquarie from $35.00 to $34.00 in a report issued on Wednesday,Benzinga reports. Macquarie currently has an outperform rating on the stock.

SGRY has been the topic of several other reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $43.00 price target on shares of Surgery Partners in a report on Friday, October 4th. StockNews.com downgraded Surgery Partners from a “hold” rating to a “sell” rating in a research note on Wednesday, August 7th. Benchmark reiterated a “buy” rating and set a $50.00 price objective on shares of Surgery Partners in a research report on Monday, August 26th. KeyCorp initiated coverage on Surgery Partners in a report on Friday, October 11th. They set a “sector weight” rating for the company. Finally, Citigroup decreased their price target on shares of Surgery Partners from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.71.

Surgery Partners Price Performance

SGRY opened at $22.95 on Wednesday. The company has a quick ratio of 1.69, a current ratio of 1.80 and a debt-to-equity ratio of 0.99. Surgery Partners has a 12-month low of $22.25 and a 12-month high of $36.92. The business has a 50 day moving average of $30.62 and a 200-day moving average of $28.45.

Surgery Partners (NASDAQ:SGRY) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.06). Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The business had revenue of $770.40 million for the quarter, compared to analyst estimates of $768.99 million. During the same period in the prior year, the business earned $0.15 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, research analysts predict that Surgery Partners will post 0.83 earnings per share for the current year.

Institutional Investors Weigh In On Surgery Partners

Large investors have recently bought and sold shares of the company. First Eagle Investment Management LLC lifted its holdings in shares of Surgery Partners by 16.5% during the 1st quarter. First Eagle Investment Management LLC now owns 339,474 shares of the company’s stock worth $10,127,000 after acquiring an additional 48,100 shares during the period. Bamco Inc. NY raised its position in Surgery Partners by 100.0% during the first quarter. Bamco Inc. NY now owns 90,000 shares of the company’s stock valued at $2,685,000 after purchasing an additional 45,000 shares in the last quarter. Lombard Odier Asset Management Europe Ltd bought a new stake in Surgery Partners during the second quarter worth $4,163,000. Rhumbline Advisers boosted its holdings in shares of Surgery Partners by 19.6% in the 2nd quarter. Rhumbline Advisers now owns 127,952 shares of the company’s stock valued at $3,044,000 after purchasing an additional 20,963 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Surgery Partners by 7,987.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,504,248 shares of the company’s stock valued at $74,701,000 after purchasing an additional 2,473,282 shares during the last quarter.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.